Previous close | 1.0600 |
Open | 1.0600 |
Bid | 0.0000 |
Ask | 2.4000 |
Strike | 135.00 |
Expiry date | 2025-01-17 |
Day's range | 1.0600 - 1.0600 |
Contract range | N/A |
Volume | |
Open interest | 11 |
Edwards Lifesciences stock underperformed its peers on Friday, sliding on light sales of its transcatheter aortic heart-valve replacements.
Lantheus' (LNTH) first-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.
Strong performance of SAPIEN 3 Ultra RESILIA platform and sustainable TAVR growth drives Edwards Lifesciences (EW) Q1 revenues.